Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)

Pfiz­er earns long-await­ed full FDA nod for Covid-19 vac­cine, a hope­ful aid in US cam­paign

The FDA on Mon­day an­nounced its full ap­proval for Pfiz­er and BioN­Tech’s mR­NA-based Covid-19 vac­cine for in­di­vid­u­als 16 and old­er, po­ten­tial­ly of­fer­ing a break­through on the PR front for the US vac­ci­na­tion cam­paign.

The vac­cine, which pre­vi­ous­ly held an emer­gency use au­tho­riza­tion from the agency, will now mar­ket as Comir­naty — a moniker the com­pa­nies had pre­vi­ous­ly an­nounced, chang­ing from the place­hold­er “Pfiz­er-BioN­Tech Covid-19 Vac­cine” name. Chil­dren be­tween the ages of 12 and 16 will still have ac­cess to the vac­cine un­der the EUA and tri­als in chil­dren younger than 12 are still on­go­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.